Skip to content

Comparison of bladder botox and tamsulosin tablets in the treatment of symptomatic benign prostatic hyperplasia (BPH) patients.

Comparison of the effect of intravesical injection of Botox with oral tamsulosin 0.4 mg in the treatment of lower urinary tract symptom disorders (LUTS) in patients with symptomatic benign prostatic hyperplasia (BPH).

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240409061460N1
Enrollment
40
Registered
2024-04-22
Start date
2024-05-21
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia. Benign neoplasm of prostate

Interventions

Intervention 1: Intervention group: Patients in this group will be injected with Botox in the bladder neck area.The way to inject Botox is that every 100 international units of Bo-A will be diluted in

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1- Prostate volume more than 30 ml 2- Obtaining a score higher than 8 from the International Prostate Symptom Score (IPSS) 3- Serum level total prostate specific antigen (tPSA) less than 10ng/mL 4- maximum urinary flow rate (Qmax) less than 16 ml/s 5- Voided volume (VV) more than 150 ml

Exclusion criteria

Exclusion criteria: 1- Having an active and recurrent urinary tract infection 2- History of previous prostatectomy 3- History of prostate cancer 4- Bladder or prostate stones 5- History of using phenylephrine, pseudoephedrine, imipramine, cholinergic, anticholinergic, estrogen, androgen and steroid since 4 weeks before the intervention 6- Biopsy from 6 weeks before the intervention 7- History of unstable angina pectoris, primary neurological disease that affects bladder function, such as multiple sclerosis, myasthenia gravis, Parkinson's 8- History of BoNT-A intraprostatic administration 9- Taking ASA, warfarin and NSAIDs from 6 days before the intervention 10- History of bladder sensitivity to BoNT-A

Design outcomes

Primary

MeasureTime frame
Maximum urinary flow rate. Timepoint: Before and 3 months after the intervention. Method of measurement: Uroflowmetry test.;Total Prostate Specific Antigen. Timepoint: Before and 3 months after the intervention. Method of measurement: ELISA test on blood sample.;Prostate volume. Timepoint: Before and 3 months after the intervention. Method of measurement: Examination of ultrasound results.;Prostate symptoms. Timepoint: Before and 3 months after the intervention. Method of measurement: International Prostate Symptom Score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDinyar Khazaeli

Ahvaz University of Medical Sciences

khazaeli-d@ajums.ac.ir+98 61 3373 8383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026